Month: June 2021


PARP inhibitors are being developed as therapeutic brokers for most cancers. Greater than six compounds have entered scientific trials. The vast majority of these compounds are β-nicotinamide adenine dinucleotide (NAD(+))-competitive inhibitors. One exception is iniparib, which has been proposed to Read more…


Impaired DNA harm response pathways might create vulnerabilities of most cancers cells that may be exploited therapeutically. One such selective vulnerability is the sensitivity of BRCA1- or BRCA2-defective tumors (therefore faulty in DNA restore by homologous recombination, HR) to inhibitors Read more…

June 2021
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930